基于亮氨酰-tRNA合成酶的药物研究进展  

Research progress in drugs based on leucyl-tRNA synthetase

作　　者：何锐 刘家族 洪庆霞 赵一同 吴成军[1] 孙铁民[1] HE Rui;LIU Jia-zu;HONG Qing-xia;ZHAO Yi-tong;WU Cheng-jun;SUN Tie-min(Innovation Laboratory of Drug Research and Design,Shenyang Pharmaceutical University,Ministry of Education,Shenyang 110016)

机构地区：[1]沈阳药科大学创新药物研究与设计教育部重点实验室,沈阳110016

出　　处：《中南药学》2020年第8期1290-1298,共9页Central South Pharmacy

基　　金：国家自然科学基金青年项目(No.81903474)。

摘　　要：氨酰-tRNA合成酶,也称氨基酸活化酶或氨酰-tRNA连接酶,是生物有机体中一类重要的酶。在蛋白质生物合成过程中,它们能够催化与其相应的tRNA之间的氨酰化反应,确保从mRNA 到蛋白质翻译过程中的高度专一性和准确性。而亮氨酰-tRNA合成酶作为其中的一员,由于具有独特的合成和编辑位点,因此以其为潜在靶点的药物研究受到了众多科研人员的青睐,本文主要综述了以亮氨酰-tRNA合成酶为靶点的药物研究进展和治疗前景。Aminoacyl-tRNA synthetase (aaRS),also known as amino acid activating enzymes or aminoacyl-tRNA ligases,are important enzymes in biological organisms.In the protein biosynthesis,they can catalyze the corresponding aminoacylation reaction between the tRNAs to ensure a high degree of specificity and accuracy in the translation from mRNA to protein.Leucyl-tRNA synthetase (LeuRS),one of aaRS members,has unique synthesis and editing sites,and a potential drug target based on LeuRS favored by many researchers.In this review,we focus on the research progress and therapeutic prospects of drugs targeting LeuRS.

关 键 词：亮氨酰-TRNA合成酶 抗菌 抗肿瘤 

分 类 号：R914[医药卫生—药物化学]